

# FY4/23 1Q Supplementary Materials

# AIN HOLDINGS INC.

September 2, 2022

# 1. Consolidated Results

$\blacksquare Y$	ea	r-	on	ı-Y	'ea	r
------------------	----	----	----	-----	-----	---

(¥ million)	FY4/22 1Q results	FY4/23 1Q results	YoY change	YoY change(%)
Net sales	75,011	81,470	+6,459	+8.6
Gross profit % of net sales	11,060 <b>14.7</b>	11,643 <b>14.3</b>	+583	+5.3
SG&A expenses % of net sales	8,448 <b>11.3</b>	8,890 <b>10.9</b>	+442	+5.2
Operating profit % of net sales	2,611 <b>3.5</b>	2,753 <b>3.4</b>	+142	+5.4
Ordinary profit % of net sales	2,864 <b>3.8</b>	3,089 <b>3.8</b>	+225	+7.9
Profit attributable to owners of parent % of net sales	1,309 <b>1.7</b>	1,704 <b>2.1</b>	+395	+30.2
Earnings per share(¥)	37.10	48.53	+11.43	+30.8

Figures in the table are rounded down

# ■Vs Plan

(¥ million)	FY4/23 1Q plan	FY4/23 1Q results	Vs plan change	Vs plan change(%)
Net sales	81,887	81,470	(417)	(0.5)
Gross profit % of net sales	12,471 <b>15.2</b>	11,643 <b>14.3</b>	(828)	(6.6)
SG&A expenses % of net sales	9,413 <b>11.5</b>	8,890 <b>10.9</b>	(523)	(5.6)
Operating profit % of net sales	3,058 <b>3.7</b>	2,753 <b>3.4</b>	(305)	(10.0)
Ordinary profit % of net sales	3,180 <b>3.9</b>	3,089 <b>3.8</b>	(91)	(2.9)
Profit attributable to owners of parent % of net sales	1,450 <b>1.8</b>	1,704 <b>2.1</b>	+254	+17.5
Earnings per share(¥)	41.19	48.53	+7.34	+17.8

Figures in the table are rounded down

# 2. Segment Information (Dispensing Pharmacy Business)

### ■ Year-on-Year

(¥ million)	FY4/22 1Q results	FY4/23 1Q results	YoY change	YoY change(%)
Net sales	66,828	72,482	+5,654	+8.5
Gross profit % of net sales	8,138 <b>12.2</b>	8,327 <b>11.5</b>	+189	+2.3
SG&A expenses % of net sales	3,396 <b>5.1</b>	3,840 <b>5.3</b>	+444	+13.1
Operating profit % of net sales	4,742 <b>7.1</b>	4,486 <b>6.2</b>	(256)	(5.4)
Segment income % of net sales	4,879 <b>7.3</b>	4,731 <b>6.5</b>	(148)	(3.0)

Figures in the table are rounded down

### ■ Vs Plan

(¥ million)	FY4/23 1Q plan	FY4/23 1Q results	Vs plan change	Vs plan change(%)	
Net sales	72,810	72,482	(328)	(0.5)	
Gross profit % of net sales	9,150 <b>12.6</b>	8,327 <b>11.5</b>	(823)	(9.0)	
SG&A expenses % of net sales	3,870 <b>5.3</b>	3,840 <b>5.3</b>	(30)	(0.8)	
Operating profit % of net sales	5,280 <b>7.3</b>	4,486 <b>6.2</b>	(794)	(15.0)	
Segment income % of net sales	5,390 <b>7.4</b>	4,731 <b>6.5</b>	(659)	(12.2)	

Figures in the table are rounded down

Segment income is adjusted to ordinary profit shown on the quarterly consolidated statement of income

Segment income is adjusted to ordinary profit shown on the quarterly consolidated statement of income

# 3. Segment Information (Cosmetic and Drug Store Business)

### ■ Year-on-Year

(¥ million)	FY4/22 1Q results	FY4/23 1Q results	YoY change	YoY change(%)
Net sales	5,063	6,086	+1,023	+20.2
Gross profit % of net sales	1,701 <b>33.6</b>	2,245 <b>36.9</b>	+544	+32.0
SG&A expenses % of net sales	2,213 <b>43.7</b>	2,098 <b>34.5</b>	(115)	(5.2)
Operating profit % of net sales	(511) -	146 <b>2.4</b>	+657	-
Segment income % of net sales	(503) -	164 <b>2.7</b>	+667	-

Figures in the table are rounded down

### ■ Vs Plan

(¥ million)	FY4/23 1Q plan	FY4/23 1Q results	Vs plan change	Vs plan change(%)	
Net sales	6,130	6,086	(44)	(0.7)	
Gross profit % of net sales	2,256 <b>36.8</b>	2,245 <b>36.9</b>	(11)	(0.5)	
SG&A expenses % of net sales	2,276 <b>37.1</b>	2,098 <b>34.5</b>	(178)	(7.8)	
Operating profit   % of net sales	(20)	146 <b>2.4</b>	+166	-	
Segment income % of net sales	(20) -	164 <b>2.7</b>	+184	-	

Figures in the table are rounded down

Segment income is adjusted to ordinary profit shown on the quarterly consolidated statement of income

Segment income is adjusted to ordinary profit shown on the quarterly consolidated statement of income

# 4. Sales Verification

■ Dispensing Pharmacy Business (YoY)				■ Dispensing Pharmacy Business (Vs Plan)				
	(%)	Net sales	Prescription volume	Average prescription price	(%)	Net sales	Prescription volume	Average prescription price
	Same store (1,044)	+0.3	+0.2	+0.1	Same store (1,044)	(0.8)	0.0	(0.8)
	Store openings in the previous year (49)	+760.3	+703.9	+7.2	Store openings in the previous year (49)	(1.9)	(3.9)	+2.1
	Total (1,210)	+8.2	+7.8	+0.4	Total (1,210)	(0.7)	(0.4)	(0.3)

# ■ Cosmetic and Drug Store Business (YoY) ■ Cosmetic and Drug Store Business (Vs Plan)

	3				3	(	
(%)	Net sales	Number of customers	Average spending per customer	(%)	Net sales	Number of customers	Average spending per customer
Same store (65)	+10.4	+16.8	(5.5)	Same store (65)	+0.7	+3.8	(3.0)
Store openings in the previous year (11)	+8,490.3	+8,039.1	+5.5	Store openings in the previous year (11)	(11.6)	(4.3)	(7.6)
Total (79)	+20.2	+27.9	(6.0)	Total (79)	(0.7)	+2.4	(3.1)

Changed accounting policies for revenue recognition from FY4/22

### 5. Consolidated Balance Sheet

### ■ Assets

(¥ million)	End-FY4/22 1Q	End-FY4/22	End-FY4/23 1Q	Change
Cash on hand and in banks	53,576	59,729	46,863	(12,866)
Notes and accounts receivable	12,338	10,110	12,697	+2,587
Inventories	15,180	14,790	19,504	+4,714
Total current assets	94,829	100,765	96,163	(4,602)
Buildings and structures,net	16,345	17,512	19,505	+1,993
Land	9,976	8,581	10,637	+2,056
Total property,plant and equipment	30,117	30,636	35,755	+5,119
Goodwill	39,079	36,352	49,344	+12,992
Total intangible fixed assets	42,788	41,219	54,479	+13,260
Investments in securities	2,638	2,503	2,649	+146
Deferred tax assets	4,633	5,319	5,957	+638
Deposits and guarantees	21,313	22,785	23,234	+449
Total investments and other assets	35,817	39,840	41,996	+2,156
Total fixed assets	108,722	111,696	132,231	+20,535
Total deferred assets	-	-	-	-
Total assets	203,552	212,461	228,394	+15,933

Figures in the table are rounded down

Change:End-FY4/23 1Q compared with end-FY4/22

# ■ Liabilities and Net Assets

(¥ million)	End-FY4/22 1Q	End-FY4/22	End-FY4/23 1Q	Change
Accounts payable	49,094	50,756	59,462	+8,706
Short-term debt	3,354	2,643	4,167	+1,524
Total current liabilities	76,816	81,805	91,402	+9,597
Long-term debt	7,507	5,815	11,218	+5,403
Total long-term liabilities	12,962	11,645	18,217	+6,572
Total liabilities	89,778	93,450	109,620	+16,170
Common stock	21,894	21,894	21,894	-
Capital surplus	20,500	20,500	20,500	-
Retained earnings	72,878	78,661	78,433	(228)
Total shareholders' equity	113,870	119,038	118,811	(227)
Total net assets	113,773	119,010	118,773	(237)
Total liabilities and net assets	203,552	212,461	228,394	+15,933

Figures in the table are rounded down

Change:End-FY4/23 1Q compared with end-FY4/22

Capital expenditures(Purchases of property, plant and equipment and intangible fixed assets + Deposits and guarantees) totaled ¥3,210million

# 6. FY4/23 Plan (Consolidated)

(¥ million)	FY4/21 results	FY4/22 results	FY4/23 plan	YoY change	YoY change (%)
Net sales	297,305	316,247	363,000	+46,753	+14.8
Gross profit % of net sales	46,155 <b>15.5</b>	49,971 <b>15.8</b>	58,720 <b>16.2</b>	+8,749	+17.5
SG&A expenses % of net sales	35,222 <b>11.8</b>	34,832 <b>11.0</b>	38,720 <b>10.7</b>	+3,888	+11.2
Operating profit % of net sales	10,932 <b>3.7</b>	15,139 <b>4.8</b>	20,000 <b>5.5</b>	+4,861	+32.1
Ordinary profit % of net sales	12,649 <b>4.3</b>	16,041 <b>5.1</b>	20,500 <b>5.6</b>	+4,459	+27.8
Profit attributable to owners of parent % of net sales	6,697 <b>2.3</b>	7,092 <b>2.2</b>	11,000 <b>3.0</b>	+3,908	+55.1
Earnings per share(¥)	189.04	201.47	313.15	+111.68	+55.4
Annual dividend (¥)	55.00	55.00	60.00	+5.00	+9.1

Figures in the table are rounded down

<sup>▶</sup> Change:FY4/23 plan compared with FY4/22 results

## 7. Transition of Store Openings

## ■ Number of Store Openings in Dispensing Pharmacy Business

	FY4/15 I	FY4/16	FY4/17	FY4/18	FY4/19	FY4/20	FY4/21	FY4/22	FY4/23 1Q
Organic	40	32	27	25	23	14	15	25	8
M&A	119	110	182	11	134	6	14	24	109
Total	754	881	1,066	1,029	1,132	1,088	1,065	1,099	1,210

## ■ Number of Store Openings in Cosmetic and Drug Store Business

	FY4/15 F	Y4/16 F	Y4/17 F	Y4/18 F	Y4/19 F	Y4/20 F	Y4/21 F	Y4/22	FY4/23 1Q
Organic	3	5	9	4	7	15	11	12	2
Total	56	52	52	48	54	63	69	78	79

### Inquiries related to this presentation should be addressed to

AIN HOLDINGS INC.
Corporate Planning Division
TEL(81)11-814-0010
FAX(81)11-814-5550
https://www.ainj.co.jp/

This document may not be reproduced or distributed to any third party without prior approval of AIN HOLDINGS INC. This document has been prepared for information purpose only and does not form part of a solicitation to sell or purchase any securities. Information contained herein may be changed or revised without prior notice. This document may contain forecasting statements as to future results of operations. No forecast statement can be guaranteed and actual results of operations may differ from those projected.

